- Home
- TNXP vs LANV Comparison
TNXP vs LANV Comparison
Compare TNXP & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- LANV
- Stock Information
- Founded
- TNXP 2007
- LANV 2015
- Country
- TNXP United States
- LANV China
- Employees
- TNXP N/A
- LANV N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- LANV Blank Checks
- Sector
- TNXP Health Care
- LANV Finance
- Exchange
- TNXP Nasdaq
- LANV Nasdaq
- Market Cap
- TNXP 335.6M
- LANV 275.9M
- IPO Year
- TNXP N/A
- LANV N/A
- Fundamental
- Price
- TNXP $51.35
- LANV $2.25
- Analyst Decision
- TNXP Buy
- LANV
- Analyst Count
- TNXP 1
- LANV 0
- Target Price
- TNXP $70.00
- LANV N/A
- AVG Volume (30 Days)
- TNXP 1.8M
- LANV 170.2K
- Earning Date
- TNXP 08-11-2025
- LANV 08-25-2025
- Dividend Yield
- TNXP N/A
- LANV N/A
- EPS Growth
- TNXP N/A
- LANV N/A
- EPS
- TNXP N/A
- LANV N/A
- Revenue
- TNXP $9,831,000.00
- LANV $340,211,202.00
- Revenue This Year
- TNXP $22.87
- LANV $11.74
- Revenue Next Year
- TNXP $711.66
- LANV $11.11
- P/E Ratio
- TNXP N/A
- LANV N/A
- Revenue Growth
- TNXP N/A
- LANV N/A
- 52 Week Low
- TNXP $6.76
- LANV $1.30
- 52 Week High
- TNXP $130.00
- LANV $2.69
- Technical
- Relative Strength Index (RSI)
- TNXP 55.76
- LANV 48.34
- Support Level
- TNXP $42.12
- LANV $2.17
- Resistance Level
- TNXP $69.97
- LANV $2.40
- Average True Range (ATR)
- TNXP 6.06
- LANV 0.14
- MACD
- TNXP 1.01
- LANV -0.01
- Stochastic Oscillator
- TNXP 45.73
- LANV 41.43
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.